Search

Your search keyword '"M.A. Gentilini"' showing total 3 results
Start Over Author "M.A. Gentilini"
3 results on '"M.A. Gentilini"'

1. Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting

Author

Silvano Piffer, Kamila Kepska, K. Henau, Bénédicte Lapôtre-Ledoux, Maja Primic-Zakelj, Anna Gavin, Anselmo Madeddu, Neville Calleja, Fabio Pannozzo, M Usala, Marc Colonna, Marià Carulla, Dyfed Wyn Huws, Jon G. Jonasson, Xavier Troussard, Antonio Ziino, Silvia Rossi, Francesco Vitale, Conchi Moreno-Iribas, Riccardo Capocaccia, Adriano Giacomin, Isabelle Konzelmann, J. Błaszczyk, Claire Schvartz, Anne-Marie Bouvier, Mohsen Mousavi, Anne-Valérie Guizard, Chakameh Safaei Diba, Maarit K. Leinonen, Laura Botta, Nadya Dimitrova, Diego Serraino, Arantza Lopez de Munain, Gemma Gatta, Anne-Sophie Woronoff, Elizabeth Van Eycken, L Benfatto, E Marani, Nea Malila, Ladislav Dušek, Mariano Santaquilani, Harry Comber, Arturo Iannelli, José María Díaz García, Maria José Bento, M. Robaszkiewicz, Stanisław Góźdź, M.A. Gentilini, Stefano Ferretti, Ana Miranda, Andrea Tavilla, Paolo Ricci, Silvia Ess, Diego Salmerón, M Autelitano, Carmen Navarro, Alessandro Barchielli, Daniela Pierannunzio, Gianbattista Spagnoli, Giedre Smailyte, Santa Pildava, Roland Stabenow, Nerea Larrañaga, Arnold Knijn, Simona Bara, Flavio Sensi, Nicolas Girard, Alice Nennecke, Fabrizio Stracci, Giovanna Tagliabue, Ana Torrella-Ramos, Massimo Rugge, Bernd Holleczek, Andrea Bordoni, Michel Velten, Rosario Tumino, David H. Brewster, Jadwiga Rachtan, Alain Monnereau, M. Sekerija, Jan Heidrich, Sabine Luttmann, Kerri Clough-Gorr, Christine Bouchardy, Véronique Bouvier, Valerio Gennaro, Rosa Filiberti, Lucia Mangone, Patrick Arveux, Brigitte Trétarre, Isabelle Baldi, Roberta De Angelis, Martina Imbimbo, Margit Mägi, Marc Maynadié, Jutta Engel, Guido Mazzoleni, Otto Visser, María José Sánchez, Jean-Michel Maury, Marina Chiara Garassino, Rafael Marcos-Gragera, E. Almar, Gabriele Schubert-Fritschle, Sandra Mallone, Jaume Galceran, Pascale Grosclaude, S Maspero, Jem Rashbass, Tom Børge Johannesen, Gonçalo Forjaz de Lacerda, Maria Michiara, Magdalena Bielska-Lasota, Ellen Benhamou, Annalisa Trama, Florence Molinié, Pina Candela, Monika Hackl, Fabio Falcini, Ian Kunkler, Antonella Sutera Sardo, Mario Fusco, Imbimbo, M, Maury, J, Grassino, M, Girard, N, and Vitale, F

Subjects
0301 basic medicine, Mesothelioma, medicine.medical_specialty, International Cooperation, Pleural Neoplasms, MEDLINE, Socio-culturale, Context (language use), Translational research, Disease, Social Networking, 03 medical and health sciences, 0302 clinical medicine, Multidisciplinary approach, Medicine, Humans, Pleural Neoplasm, Intensive care medicine, business.industry, General Medicine, Thymus Neoplasms, medicine.disease, Clinical trial, Europe, Survival Rate, 030104 developmental biology, Clinical research, Oncology, 030220 oncology & carcinogenesis, Surgery, business, Delivery of Health Care, mesothelioma, thymic tumours, clinical trials, Human
Abstract

The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMIG (International Mesothelioma Interest Group) and ITMIG (International Thymic Malignancy Interest Group) provide infrastructure for global collaboration, and there are many advantages to having strong regional groups working on the same issues. There may be regional differences in risk factors, susceptibility, management and outcomes. The ability to address questions both regionally as well as globally is ideal to develop a full understanding of mesothelioma and thymic malignancies. In Europe, through the integration of national networks with EURACAN, the collaboration with academic societies and international groups, the development of networks in thoracic oncology provides multiplex integration of clinical care and research, ultimately ensuring equal access to high quality care to all patients, with the opportunity of conducting high level clinical and translational research projects.

Published
2017

2. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

Author

Fabio Falcini, Charles A. Stiller, Diego Serraino, Antonella Sutera Sardo, Kerri Clough-Gorr, Mario Fusco, Véronique Bouvier, Silvia Francisci, Alain Monnereau, Carmen Navarro, Alessandro Barchielli, Annalisa Trama, Bénédicte Lapôtre-Ledoux, Stanislaw Gózdz, Isabelle Konzelmann, J. Błaszczyk, Laura Botta, Simona Bara, Flavio Sensi, Gonçalo Forjaz de Lacerda, Nadya Dimitrova, Lucia Mangone, Pamela Minicozzi, Maria Michiara, Neville Calleja, M Usala, E Marani, Innos Kaire, Tom Børge Johannesen, Ladislav Dušek, Sabine Luttmann, M Autelitano, Anne Sophie Woronoff, Vincent K Y Ho, Francesco Vitale, Silvano Piffer, Jan Maarten van der Zwan, Dyfed Wyn Huws, David H. Brewster, Margit Mägi, Zdravka Valerianova, Anna Luisa Caiazzo, Maja Primic Žakelj, Adriano Giacomin, E. Almar, F Bella, Ellen Benhamou, Arantza Lopez de Munain, Patrick Arveux, Claire Schvartz, José María Díaz García, M. Robaszkiewicz, Isabelle Baldi, Otto Visser, Mohsen Mousavi, Maria José Bento, Lesley A. Anderson, Chakameh Safaei Diba, Mariano Santaquilani, Gemma Gatta, Tina Žagar, Pina Candela, Jadwiga Rachtan, María José Sánchez, Andrea Bordoni, Monika Hackl, Gabriele Schubert-Fritschle, Nea Malila, Diego Salmerón, Massimo Rugge, Carmen Tereanu, Maarit K. Leinonen, Jem Rashbass, Arturo Iannelli, Milena Sant, Antonino Ziino Colanino, Marià Carulla, Christine Bouchardy, Keiu Paapsi, Marc Colonna, Jon G. Jonasson, Brigitte Trétarre, A.V. Guizard, Riccardo Capocaccia, Xavier Troussard, Jan Heidrich, Dominic Agius, Kamila Kepska, Daniela Pierannunzio, Santa Pildava, Stefano Ferretti, Silvia Rossi, Guido Mazzoleni, Rafael Marcos-Gragera, Giedre Smailyte, Gianbattista Spagnoli, Nancy Van Damme, Roland Stabenow, Anna Gavin, Paolo Baili, Anselmo Madeddu, Fabio Pannozzo, M. Sekerija, Silvia Ess, Sandra Mallone, Rosa Filiberti, Pascale Grosclaude, Florence Molinié, S Maspero, Alice Nennecke, Rosario Tumino, Renée Otter, Ana Torrella-Ramos, Fabrizio Stracci, Giovanna Tagliabue, Michel Velten, Andrea Tavilla, Marc Maynadié, Arnold Knijn, Conchi Moreno-Iribas, Eva Ardanaz, M.A. Gentilini, Paolo Ricci, Liesbet Van Eycken, Ana Miranda, Sabine Siesling, Nerea Larrañaga, Roberta De Angelis, Harry Comber, Paolo Collarile, K. Henau, Bernd Holleczek, Anne Marie Bouvier, Jutta Engel, Jaume Galceran, Gatta G., Capocaccia R., Botta L., Mallone S., De Angelis R., Ardanaz E., Comber H., Dimitrova N., Leinonen M.K., Siesling S., van der Zwan J.M., Van Eycken L., Visser O., Zakelj M.P., Anderson L.A., Bella F., Kaire I., Otter R., Stiller C.A., Trama A., Hackl M., Henau K., Van Damme N., Valerianova Z., Sekerija M., Dusek L., Magi M., Paapsi K., Malila N., Velten M., Troussard X., Bouvier V., Guizard A.-V., Bouvier A.-M., Arveux P., Maynadie M., Woronoff A.-S., Robaszkiewicz M., Baldi I., Monnereau A., Tretarre B., Colonna M., Molinie F., Bara S., Schvartz C., Lapotre-Ledoux B., Grosclaude P., Stabenow R., Luttmann S., Nennecke A., Engel J., SchubertFritschle G., Heidrich J., Holleczek B., Jonasson J.G., Clough-Gorr K., Mazzoleni G., Giacomin A., Sardo A.S., Barchielli A., Serraino D., Collarile P., Pannozzo F., Ricci P., Autelitano M., Spagnoli G., Fusco M., Usala M., Vitale F., Michiara M., Tumino R., Mangone L., Falcini F., Ferretti S., Filiberti R.A., Marani E., Caiazzo A.L., Iannelli A., Sensi F., Piffer S., Gentilini M., Madeddu A., Colanino A.Z., Maspero S., Candela P., Stracci F., Tagliabue G., Rugge M., Baili P., Minicozzi P., Sant M., Tereanu C., Francisci S., Tavilla A., Pierannunzio D., Rossi S., Santaquilani M., Knijn A., Pildava S., Smailyte G., Calleja N., Agius D., Johannesen T.B., Rachtan J., Gozdz S., Blaszczyk J., Kepska K., Lacerda G.F.D., Bento M.J., Miranda A., Diba C.S., Zagar T., Almar E., Larranaga N., Munain A.L.D., Torrella-Ramos A., Garcia J.M.D., Marcos-Gragera R., Sanchez M.J., Navarro C., Salmeron D., Moreno-Iribas C., Galceran J., Carulla M., Mousavi M., Bouchardy C., Ess S.M., Bordoni A., Konzelmann I., Rashbass J., Gavin A., Brewster D.H., Huws D.W., Ho V.K., and Benhamou E.

Subjects
Male, 0301 basic medicine, Pathology, population-based registries, Cancer Care Facilities, Delivery of Health Care, Europe, Female, Hospitalization, Humans, Incidence, Neoplasms, Rare Diseases, Registries, Survival Rate, Oncology, 0302 clinical medicine, Medicine, media_common, Tumors -- Treatment -- Europe, education.field_of_study, Relative survival, Incidence (epidemiology), RARECARE project, 030220 oncology & carcinogenesis, medicine.medical_specialty, Health surveys, Population, Socio-culturale, 03 medical and health sciences, SDG 3 - Good Health and Well-being, media_common.cataloged_instance, Cancer -- Mortality, Risk factor, European union, education, Survival rate, Oncology, cancer burden, incidence, rare cancer,population-based registries, rare cancers, cancer registry, RARECARE, business.industry, Rare cancer, Cancer -- Patients -- Long-term care, Cancer registry, 030104 developmental biology, cancer burden, business, Demography, Rare disease
Abstract

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calculated as the number of new cases divided by the corresponding total person-years in the population. 5-year relative survival was calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, the Netherlands, Slovenia, and the Navarra region in Spain) provided additional data for hospitals treating about 220 000 cases diagnosed in 2000–07. We also calculated hospital volume admission as the number of treatments provided by each hospital rare cancer group sharing the same referral pattern. Findings: Rare cancers accounted for 24% of all cancers diagnosed in the EU during 2000–07. The overall incidence rose annually by 0.5% (99·8% CI 0·3–0·8). 5-year relative survival for all rare cancers was 48·5% (95% CI 48·4 to 48·6), compared with 63·4% (95% CI 63·3 to 63·4) for all common cancers. 5-year relative survival increased (overall 2·9%, 95% CI 2·7 to 3·2), from 1999–2001 to 2007–09, and for most rare cancers, with the largest increases for haematological tumours and sarcomas. The amount of centralisation of rare cancer treatment varied widely between cancers and between countries. The Netherlands and Slovenia had the highest treatment volumes. Interpretation: Our study benefits from the largest pool of population-based registries to estimate incidence and survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk factors, improved diagnosis, and registration problems. Survival could be improved by early diagnosis, new treatments, and improved case management. The centralisation of treatment could be improved in the seven European countries we studied., peer-reviewed

Published
2017
Full Text
View/download PDF

3. Long-term survival, prevalence, and cure of cancer: A population-based estimation for 818 902 Italian patients and 26 cancer types

Author

Carlotta Buzzoni, Diego Serraino, Giuseppe Michele Masanotti, A. P. Dei Tos, Roberto Zanetti, G Senatore, Silvia Francisci, A.C. Fanetti, M Autelitano, Umberto Tirelli, R. De Angelis, Maria Michiara, M. Vercelli, Emanuele Crocetti, Rosanna Cusimano, R. Capocaccia, M.A. Gentilini, Anna Gigli, Ettore Bidoli, Saverio Virdone, Antonella Zucchetto, Massimo Federico, D Pirino, Stefano Ferretti, Fabio Pannozzo, A. Bulatko, Marine Castaing, L. Dal Maso, Paolo Baili, Massimo Vicentini, M Fusco, Adele Caldarella, Fabio Falcini, Adriano Giacomin, F Tisano, Gemma Gatta, Paolo Contiero, and Stefano Guzzinati

Subjects
Adult, Male, medicine.medical_specialty, Long-term survival, prevalence, and cure of cancer, Adolescent, Survival, prevalence,cancer cure, Italy, Survival, Epidemiology, Population, Cancer cure, Italy, Prevalence, Hematology, Oncology, Socio-culturale, Disease-Free Survival, italy, cancer cure, survival, Prostate cancer, Neoplasms, Internal medicine, Ethnicity, medicine, Humans, education, Multiple myeloma, Aged, Demography, Estimation, education.field_of_study, Relative survival, business.industry, Mortality rate, Cancer, Original Articles, Middle Aged, medicine.disease, Surgery, Lymphoma, Female, business
Abstract

Original, population-based estimates of indicators of long-term survival and cure in cancer patients are provided. More than a quarter of cancer patients in Italy have reached death rates similar to those of the general population. Nearly three quarters of them will not die as a result of cancer. These estimates are potentially helpful to health-care planners, clinicians, and patients., Background Persons living after a cancer diagnosis represent 4% of the whole population in high-income countries. The aim of the study was to provide estimates of indicators of long-term survival and cure for 26 cancer types, presently lacking. Patients and methods Data on 818 902 Italian cancer patients diagnosed at age 15–74 years in 1985–2005 were included. Proportions of patients with the same death rates of the general population (cure fractions) and those of prevalent patients who were not at risk of dying as a result of cancer (cure prevalence) were calculated, using validated mixture cure models, by cancer type, sex, and age group. We also estimated complete prevalence, conditional relative survival (CRS), time to reach 5- and 10-year CRS >95%, and proportion of patients living longer than those thresholds. Results The cure fractions ranged from >90% for patients aged 95% were both reached in 95% after 19 and 25 years, respectively, and in 15 and 18 years for prostate cancer patients. Five-year CRS remained 25 years after cancer diagnosis in patients with liver and larynx cancers, non-Hodgkin lymphoma, myeloma, and leukaemia. Overall, the cure prevalence was 67% for men and 77% for women. Therefore, 21% of male and 31% of female patients had already reached 5-year CRS >95%, whereas 18% and 25% had reached 10-year CRS >95%. Conclusions A quarter of Italian cancer patients can be considered cured. This observation has a high potential impact on health planning, clinical practice, and patients' perspective.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results